2026 Q1 -tulosraportti
63 päivää sitten
‧1 t 2 min
18,00 DKK/osake
Viimeisin osinko
5,29%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 29 | - | - | ||
| 162 | - | - | ||
| 22 | - | - | ||
| 313 | - | - | ||
| 412 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 | ||
2025 Q2 -tulosraportti 6.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·12 t sittenIf Niels. B. Christiansen can do the same with Coloplast as he has done in Danfoss and LEGO, then it will be good. He understands how to wring the synergies out of operations and at the same time have a commercial eye for the future. The question is merely whether he is able to do it from the board, when he is not at the helm. That is quite interesting. I am positive, and will start following the company more closely, and need to have an entry level determined soon. PS. The Pay-out ratio is also starting to look like something.
·2 päivää sittenNot much confidence from Goldmann😅
·1 päivä sitten · MuokattuI would probably say I partially disagree with Goldmann here. Over a single year, there isn't much Coloplast can manage to fix, e.g., earnings and growth. This naturally makes the stock uninteresting, as it cannot skyrocket. However, this does not change Coloplast's potential in the 5-year term. The Impact-4 strategy aims to achieve the deserved high return on the preceding strategy. Live off organic growth, and be happy with the defensive markets, and absolutely be happy with the over 5% annual dividend, on a stock that is historically very undervalued. I would at least rate COLO as "hold". But again, I am not an analyst, or an advisor. So I can't say much.- ·3.4.I finished writing my SOP for HHX 3.G last week, and I would love to share it with you all here on the forum. I have provided a summary of the report below. The comment section will go deeper into the numbers: Summary: This report investigates why Coloplast's stock price has fallen significantly since 2021, and whether the stock constitutes a good investment opportunity today. The report answers this through a characteristic of Coloplast, an account of the fundamental analysis theorists, Benjamin Graham, Warren Buffett and Philip Fisher, as well as a qualitative and quantitative fundamental analysis of the company, supplemented by a small comparative analysis against the competitor Smith & Nephew. Coloplast is a Danish medtech company with market leader status in several of its core markets and steadily growing revenue. The stock price drop of 63.8% from November 2021 to March 2026 is due to a combination of external factors such as rising interest rates and Chinese protectionism, but primarily internal fundamental problems. The Strive25 strategy's acquisition of Atos Medical and Kerecis for a total of DKK 25 billion strongly pressured margins and financial costs, and management's lack of execution power resulted in the firing of CEO Kristian Villumsen in May 2025. Looking ahead, the Gordon Growth Model indicates an intrinsic value far above the current price, and a forward P/E of 18,70 signals an expectation of rising future earnings. The new CEO Gavin Wood and the more focused Impact4 strategy send positive signals. The overall assessment is that Coloplast constitutes a potential investment opportunity for the long-term and risk-tolerant investor, while the large debt burden and management uncertainty make the stock unsuitable for the more cautious.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
63 päivää sitten
‧1 t 2 min
18,00 DKK/osake
Viimeisin osinko
5,29%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 t sittenIf Niels. B. Christiansen can do the same with Coloplast as he has done in Danfoss and LEGO, then it will be good. He understands how to wring the synergies out of operations and at the same time have a commercial eye for the future. The question is merely whether he is able to do it from the board, when he is not at the helm. That is quite interesting. I am positive, and will start following the company more closely, and need to have an entry level determined soon. PS. The Pay-out ratio is also starting to look like something.
- ·2 päivää sittenNot much confidence from Goldmann😅·1 päivä sitten · MuokattuI would probably say I partially disagree with Goldmann here. Over a single year, there isn't much Coloplast can manage to fix, e.g., earnings and growth. This naturally makes the stock uninteresting, as it cannot skyrocket. However, this does not change Coloplast's potential in the 5-year term. The Impact-4 strategy aims to achieve the deserved high return on the preceding strategy. Live off organic growth, and be happy with the defensive markets, and absolutely be happy with the over 5% annual dividend, on a stock that is historically very undervalued. I would at least rate COLO as "hold". But again, I am not an analyst, or an advisor. So I can't say much.
- ·3.4.I finished writing my SOP for HHX 3.G last week, and I would love to share it with you all here on the forum. I have provided a summary of the report below. The comment section will go deeper into the numbers: Summary: This report investigates why Coloplast's stock price has fallen significantly since 2021, and whether the stock constitutes a good investment opportunity today. The report answers this through a characteristic of Coloplast, an account of the fundamental analysis theorists, Benjamin Graham, Warren Buffett and Philip Fisher, as well as a qualitative and quantitative fundamental analysis of the company, supplemented by a small comparative analysis against the competitor Smith & Nephew. Coloplast is a Danish medtech company with market leader status in several of its core markets and steadily growing revenue. The stock price drop of 63.8% from November 2021 to March 2026 is due to a combination of external factors such as rising interest rates and Chinese protectionism, but primarily internal fundamental problems. The Strive25 strategy's acquisition of Atos Medical and Kerecis for a total of DKK 25 billion strongly pressured margins and financial costs, and management's lack of execution power resulted in the firing of CEO Kristian Villumsen in May 2025. Looking ahead, the Gordon Growth Model indicates an intrinsic value far above the current price, and a forward P/E of 18,70 signals an expectation of rising future earnings. The new CEO Gavin Wood and the more focused Impact4 strategy send positive signals. The overall assessment is that Coloplast constitutes a potential investment opportunity for the long-term and risk-tolerant investor, while the large debt burden and management uncertainty make the stock unsuitable for the more cautious.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 29 | - | - | ||
| 162 | - | - | ||
| 22 | - | - | ||
| 313 | - | - | ||
| 412 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 | ||
2025 Q2 -tulosraportti 6.5.2025 |
2026 Q1 -tulosraportti
63 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 | ||
2025 Q2 -tulosraportti 6.5.2025 |
18,00 DKK/osake
Viimeisin osinko
5,29%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·12 t sittenIf Niels. B. Christiansen can do the same with Coloplast as he has done in Danfoss and LEGO, then it will be good. He understands how to wring the synergies out of operations and at the same time have a commercial eye for the future. The question is merely whether he is able to do it from the board, when he is not at the helm. That is quite interesting. I am positive, and will start following the company more closely, and need to have an entry level determined soon. PS. The Pay-out ratio is also starting to look like something.
- ·2 päivää sittenNot much confidence from Goldmann😅·1 päivä sitten · MuokattuI would probably say I partially disagree with Goldmann here. Over a single year, there isn't much Coloplast can manage to fix, e.g., earnings and growth. This naturally makes the stock uninteresting, as it cannot skyrocket. However, this does not change Coloplast's potential in the 5-year term. The Impact-4 strategy aims to achieve the deserved high return on the preceding strategy. Live off organic growth, and be happy with the defensive markets, and absolutely be happy with the over 5% annual dividend, on a stock that is historically very undervalued. I would at least rate COLO as "hold". But again, I am not an analyst, or an advisor. So I can't say much.
- ·3.4.I finished writing my SOP for HHX 3.G last week, and I would love to share it with you all here on the forum. I have provided a summary of the report below. The comment section will go deeper into the numbers: Summary: This report investigates why Coloplast's stock price has fallen significantly since 2021, and whether the stock constitutes a good investment opportunity today. The report answers this through a characteristic of Coloplast, an account of the fundamental analysis theorists, Benjamin Graham, Warren Buffett and Philip Fisher, as well as a qualitative and quantitative fundamental analysis of the company, supplemented by a small comparative analysis against the competitor Smith & Nephew. Coloplast is a Danish medtech company with market leader status in several of its core markets and steadily growing revenue. The stock price drop of 63.8% from November 2021 to March 2026 is due to a combination of external factors such as rising interest rates and Chinese protectionism, but primarily internal fundamental problems. The Strive25 strategy's acquisition of Atos Medical and Kerecis for a total of DKK 25 billion strongly pressured margins and financial costs, and management's lack of execution power resulted in the firing of CEO Kristian Villumsen in May 2025. Looking ahead, the Gordon Growth Model indicates an intrinsic value far above the current price, and a forward P/E of 18,70 signals an expectation of rising future earnings. The new CEO Gavin Wood and the more focused Impact4 strategy send positive signals. The overall assessment is that Coloplast constitutes a potential investment opportunity for the long-term and risk-tolerant investor, while the large debt burden and management uncertainty make the stock unsuitable for the more cautious.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 29 | - | - | ||
| 162 | - | - | ||
| 22 | - | - | ||
| 313 | - | - | ||
| 412 | - | - |
Välittäjätilasto
Dataa ei löytynyt